The incidence of stroke continues to increase for adults and children living with sickle cell disease (SCD) despite the Stroke Prevention Trial in Sickle Cell Anemia (STOP) establishing standards of care like transfusions and tests to measure blood flow in the brain for those deemed high-risk, according to a study published today in Blood.
ZyVersa’s cholesterol efflux mediator gains patent in Europe
VAR 200 is claimed to eliminate accumulated lipids from the kidney. Credit: Robina Weermeijer on Unsplash. ZyVersa Therapeutics has received a patent from the European Patent
July 10, 2023